However, GLP-1 ARs should be considered as a therapeutic option also in the context of comorbidities of BED since the beneficial influence of GLP-1 agonists on metabolic health, impairment of which is a common concern in BED patients, has also been demonstrated [75]. This evidence concerns the gene GLP1R and X-linked cone dysfunction syndrome with myopia.